Table 1 demonstrates that RRMS patients showed significantly higher IgG, IgA, and IgM responses to MBP, PLP, MOG-35–55, MOG-31–55, CIT-MOG, MAG-37–60, and GLIAL-CAM-370–399, compared to the healthy control group. The gene discussed is CD79A; the disease is relapsing-remitting multiple sclerosis.